Article Details

Pfizer's hemophilia B gene therapy succeeds in late-stage study | The Mighty 790 KFGO

Retrieved on: 2022-12-29 12:27:22

Tags for this article:

Click the tags to see associated articles and topics

Pfizer's hemophilia B gene therapy succeeds in late-stage study | The Mighty 790 KFGO. View article details on hiswai:

Excerpt

The drugmaker licensed its hemophilia B gene therapy from Roche's Spark Therapeutics unit in 2014 for a $20-million upfront payment.

Article found on: kfgo.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up